Home About us Events Media data Subscribe Links News Email alert Search Contact us Blog  
Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To view this article:
Existing subscribers please log in:
  
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 		 

Click here to view
our current issue
 
 

Fully Human Domain Antibody Therapeutics: The Best of Both Worlds

By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential.

Robert Connelly at Domantis (September 2005)

Keywords: Fully Human Domain Antibody Therapeutics benefits small molecule drugs strong therapeutic commercial potential

    View full article    |    Back to Biopharma section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | caitlin@samedanltd.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |